J. H. Doroshow

A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.

Wong JYC, David Z. J. Chu, Dave Yamauchi et al. · PubMed · 2000 · 87 citations

Immunology, Immunoediting, 90Yttrium-labeled Anti-carcinoembryonic Antigen +16

Phase II Studies of Recombinant Human Interleukin-4 in Advanced Renal Cancer and Malignant Melanoma

Kim Margolin, Frederick R. Aronson, Mario Sznol et al. · Journal of Immunotherapy · 1994 · 69 citations

HT1080/DR4: A P-Glycoprotein-Negative Human Fibrosarcoma Cell Line Exhibiting Resistance to Topoisomerase II-Reactive Drugs Despite the Presence of a Drug-Sensitive Topoisomerase II

Leonard A. Zwelling, Marilyn L. Slovak, J. H. Doroshow et al. · JNCI Journal of the National Cancer Institute · 1990 · 58 citations

Phase I Study of High-Dose Continuous-Infusion Recombinant Interleukin-2 and Autologous Lymphokine-Activated Killer Cells in Patients With Metastatic or Unresectable Malignant Melanoma and Renal Cell Carcinoma

Ellen R. Gaynor, Geoffrey R. Weiss, Kim Margolin et al. · JNCI Journal of the National Cancer Institute · 1990 · 47 citations

Technical aspects of intraperitoneal chemotherapy in abdominal carcinomatosis

Patricia S. Braly, J. H. Doroshow, Sheila Hoff · Gynecologic Oncology · 1986 · 43 citations

Surgical Oncology, Gastrointestinal Oncology, Medicine +4